105 results
425
SPRC
SciSparc Ltd
12 Apr 24
Business combination disclosure
9:23am
and when the Merger will be consummated; the expected benefits of and potential value created by the proposed Merger for the shareholders of the Company … to be an employee of the Company by any applicable Tax authority; and
(xxiv) the Company did not apply for any tax benefits under the Law for the Encouragement
6-K
EX-99.1
SPRC
SciSparc Ltd
11 Apr 24
Agreement and Plan of Merger
4:05pm
applicable Tax authority; and
(xxiv) the Company did not apply for any tax benefits under the Law for the Encouragement of Capital Investments, 5719-1959.
(b … or retention, deferred compensation, incentive compensation, pension and severance benefits. “Company Benefit Plan” means each pension, profit sharing, bonus
6-K
SPRC
SciSparc Ltd
11 Apr 24
Agreement and Plan of Merger
4:05pm
of the Merger and whether and when the Merger will be consummated; the expected benefits of and potential value created by the proposed Merger
6-K
EX-99.2
SPRC
SciSparc Ltd
11 Apr 24
Agreement and Plan of Merger
4:05pm
ownership or incidence of ownership of or with respect to any Covered Shares. All rights, ownership and economic benefits of and relating to the Covered
6-K
EX-99.2
lqng5tw2b
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
F-1
EX-10.7
73li ucky6mq5m0
27 Feb 24
Registration statement (foreign)
4:15pm
F-1
b8yag3ze1xhkzkp r1
27 Feb 24
Registration statement (foreign)
4:15pm
6-K
EX-4.1
njfci 4o6z
25 Jan 24
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
9:05am
6-K
EX-4.1
j7bfto 0i0
28 Nov 23
Report of Foreign Private Issuer
4:01pm
6-K
EX-99.1
9pdoyi6yysv0k0 mcup
24 Oct 23
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
7:54am
6-K
EX-99.1
pwv7dryu1vnhcl
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-4.1
vslh6yyqq4brf
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
EX-10.2
u3jqt1 jds7er
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
EX-10.4
0bdtuulplhknnmdbog
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
EX-99.1
2aglrldc8z o50xd4c
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
EX-1.1
7qmr 10dfdm0q0f8coq
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
6-K
EX-99.1
txp49 ffa648fuv0
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
EX-99.1
fhzzlw6l3eulv3 9thmk
16 May 23
At-The-Market Issuance Sales Agreement
8:06pm